Evaluation of Multi-Target and Single-Target Liposomal Drugs for the Treatment of Gastric Cancer

Chen, Chien Ho; Liu, Der Zen; Fang, Hsu Wei; Liang, Hong; Yang, Tzu Sheng; Lin, Shyr Yi

doi:10.1271/bbb.80096

Cited by 23 publications

(18 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the liposomes can be functionalized with ligands for tumor-specific receptors, such as transferrin, folate, and integrin [150,151]. Recent advancements report the targeted nanoliposomal delivery of octreotide to the somatostatin receptor in gastric cancer [152]. On the other hand, targeted nanoconjugates are not yet effective anti-cancer agents, because they do not have easily reproducible synthesis and the surface targets display a heterogeneous intra-tumoral distribution making uniform dispersal difficult.…”

Section: Use Of Nanotechnology To Develop Mtismentioning

confidence: 99%

Use of Nanotechnology to Develop Multi-Drug Inhibitors for Cancer Therapy

Gowda¹,

Jones

Banerjee³

et al. 2013

J Nanomed Nanotechnol

View full text Add to dashboard Cite

Therapeutic agents that inhibit a single target often cannot combat a multifactorial disease such as cancer. Thus, multi-target inhibitors (MTIs) are needed to circumvent complications such as the development of resistance. There are two predominant types of MTIs, (a) single drug inhibitor (SDIs) that affect multiple pathways simultaneously, and (b) combinatorial agents or multi-drug inhibitors (MDIs) that inhibit multiple pathways. Single agent multi-target kinase inhibitors are amongst the most prominent class of compounds belonging to the former, whereas the latter includes many different classes of combinatorial agents that have been used to achieve synergistic efficacy against cancer. Safe delivery and accumulation at the tumor site is of paramount importance for MTIs because inhibition of multiple key signaling pathways has the potential to lead to systemic toxicity. For this reason, the development of drug delivery mechanisms using nanotechnology is preferable in order to ensure that the MDIs accumulate in the tumor vasculature, thereby increasing efficacy and minimizing off-target and systemic side effects. This review will discuss how nanotechnology can be used for the development of MTIs for cancer therapy and also it concludes with a discussion of the future of nanoparticle-based MTIs as well as the continuing obstacles being faced during the development of these unique agents.’

show abstract

Section: Use Of Nanotechnology To Develop Mtismentioning

confidence: 99%

Use of Nanotechnology to Develop Multi-Drug Inhibitors for Cancer Therapy

Gowda¹,

Jones

Banerjee³

et al. 2013

J Nanomed Nanotechnol

View full text Add to dashboard Cite

show abstract

“…Moreover, liposomes rapidly penetrate the dermal barrier, making the delivery of water-soluble compounds as effective as that of lipid-soluble compounds (24). In contrast with other drug carriers such as DMSO (25), liposomes are entirely non-toxic to human skin since they are composed of naturally occurring biodegradable compartments (26).…”

Section: Introductionmentioning

confidence: 99%

Nanoliposomes of L-lysine-conjugated poly(aspartic acid) Increase the Generation and Function of Bone Marrow-derived Dendritic Cells

Kim

Ji³

et al. 2011

Immune Netw

View full text Add to dashboard Cite

BackgroundBiodegradable polymers have increasingly been recognized for various biological applications in recent years. Here we examined the immunostimulatory activities of the novel poly(aspartic acid) conjugated with L-lysine (PLA).MethodsPLA was synthesized by conjugating L-lysine to aspartic acid polymer. PLA-nanoliposomes (PLA-NLs) were prepared from PLA using a microfluidizer. The immunostimulatory activities of PLA-NLs were examined in mouse bone marrow-derived dendritic cells (BM-DCs).ResultsPLA-NLs increased the number of BM-DCs when added to cultures of GM-CSF-induced DC generation on day 4 after the initiation of cultures. Examination of the phenotypic properties showed that BM-DCs generated in the presence of PLA-NLs are more mature in terms of the expression of MHC class II molecules and major co-stimulatory molecules than BM-DCs generated in the absence of PLA-NLs. In addition, the BM-DCs exhibited enhanced capability to produce cytokines, such as IL-6, IL-12, TNF-α and IL-1β. Allogeneic mixed lymphocyte reactions also confirmed that the BMDCs were more stimulatory on allogeneic T cells. PLA- NL also induced further growth of immature BM-DCs that were harvested on day 8.ConclusionThese results show that PLA-NLs induce the generation and functional activities of BM-DCs, and suggest that PLA-NLs could be immunostimulating agents that target DCs.

show abstract

“…48,49 Moreover, liposomes rapidly penetrate the dermal barrier making the delivery of water-soluble compounds as effective as lipid-soluble drugs. 50 We speculate that a combination of pyruvates with scavengers/antioxidants encapsulated in the liposomes for optimal local delivery will be therapeutically beneficial against HD-induced skin injury. …”

Section: Discussionmentioning

confidence: 96%

Sodium Pyruvate Modulates Cell Death Pathways in HaCaT Keratinocytes Exposed to Half-Mustard Gas

et al. 2011

View full text Add to dashboard Cite

2-Chloroethyl ethyl sulfide (CEES) or half-mustard gas, a sulfur mustard (HD) analog, is a genotoxic agent that causes oxidative stress and induces both apoptotic and necrotic cell death. Sodium pyruvate induced a necrosis-to-apoptosis shift in HaCaT cells exposed to CEES levels ≤ 1.5 mmol/L and lowered markers of DNA damage, oxidative stress, and inflammation. This study provides a rationale for the future development of multicomponent therapies for HD toxicity in the skin. We hypothesize that a combination of pyruvates with scavengers/antioxidants encapsulated in liposomes for optimal local delivery should be therapeutically beneficial against HD-induced skin injury. However, the latter suggestion should be verified in animal models exposed to HD.

show abstract

Evaluation of Multi-Target and Single-Target Liposomal Drugs for the Treatment of Gastric Cancer

Cited by 23 publications

References 43 publications

Use of Nanotechnology to Develop Multi-Drug Inhibitors for Cancer Therapy

Use of Nanotechnology to Develop Multi-Drug Inhibitors for Cancer Therapy

Nanoliposomes of L-lysine-conjugated poly(aspartic acid) Increase the Generation and Function of Bone Marrow-derived Dendritic Cells

Sodium Pyruvate Modulates Cell Death Pathways in HaCaT Keratinocytes Exposed to Half-Mustard Gas

Contact Info

Product

Resources

About